204 related articles for article (PubMed ID: 17412849)
1. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Shi L; Ascher-Svanum H; Zhu B; Faries D; Montgomery W; Marder SR
Psychiatr Serv; 2007 Apr; 58(4):482-8. PubMed ID: 17412849
[TBL] [Abstract][Full Text] [Related]
2. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.
Ascher-Svanum H; Peng X; Faries D; Montgomery W; Haddad PM
BMC Psychiatry; 2009 Jul; 9():46. PubMed ID: 19640279
[TBL] [Abstract][Full Text] [Related]
4. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.
Zhu B; Ascher-Svanum H; Shi L; Faries D; Montgomery W; Marder SR
Psychiatr Serv; 2008 Mar; 59(3):315-7. PubMed ID: 18308914
[TBL] [Abstract][Full Text] [Related]
5. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.
Valenstein M; Copeland LA; Owen R; Blow FC; Visnic S
J Clin Psychiatry; 2001 Jul; 62(7):545-51. PubMed ID: 11488366
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
7. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Stanković Z; Ille T
Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
[TBL] [Abstract][Full Text] [Related]
8. Rehospitalization risk with second-generation and depot antipsychotics.
Conley RR; Kelly DL; Love RC; McMahon RP
Ann Clin Psychiatry; 2003 Mar; 15(1):23-31. PubMed ID: 12839430
[TBL] [Abstract][Full Text] [Related]
9. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
10. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
[TBL] [Abstract][Full Text] [Related]
11. Bromperidol decanoate (depot) for schizophrenia.
Purgato M; Adams CE
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD001719. PubMed ID: 23152208
[TBL] [Abstract][Full Text] [Related]
12. Bromperidol decanoate (depot) for schizophrenia.
Purgato M; Adams CE
Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678
[TBL] [Abstract][Full Text] [Related]
13. Depot bromperidol decanoate for schizophrenia.
Wong D; Adams CE; David A; Quraishi SN
Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450
[TBL] [Abstract][Full Text] [Related]
14. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
Gutwinski S; Müller P; Koller M
Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
[TBL] [Abstract][Full Text] [Related]
15. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.
Kreyenbuhl JA; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Psychiatr Serv; 2007 Apr; 58(4):489-95. PubMed ID: 17412850
[TBL] [Abstract][Full Text] [Related]
16. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
17. Who receives long-acting antipsychotic medications?
Glazer WM
Psychiatr Serv; 2007 Apr; 58(4):437. PubMed ID: 17412839
[No Abstract] [Full Text] [Related]
18. Excessive antipsychotic dosing in 2 U.S. State hospitals.
Diaz FJ; De Leon J
J Clin Psychiatry; 2002 Nov; 63(11):998-1003. PubMed ID: 12444813
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of inpatient depot antipsychotic prescribing.
Pabis DJ; Dorson PG; Crismon ML
Ann Pharmacother; 1996 Dec; 30(12):1381-6. PubMed ID: 8968447
[TBL] [Abstract][Full Text] [Related]
20. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.
Turner M; Eerdekens E; Jacko M; Eerdekens M
Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
